Key Takeaways
- • Galderma, the Swiss skincare company, agreed to acquire ZO Skin Health, a U.S. medical skincare competitor, from Blackstone and other shareholders for $1.5 billion, according to Law360.
- • The deal adds ZO Skin Health to Galderma's dermatology portfolio, extending its presence in medical skincare.
- • Ropes & Gray advised Galderma on the transaction, per the headline of the Law360 report.
- • The announcement was made Wednesday, October 14, 2026.
Summary
Swiss skincare company Galderma said Wednesday that it has agreed to acquire ZO Skin Health, a U.S. competitor in medical skincare, from Blackstone and other shareholders for $1.5 billion, according to a Law360 report dated October 14, 2026. The acquisition is intended to add ZO Skin Health to Galderma's dermatology portfolio.
Law360 reported that Ropes & Gray acted as legal counsel to Galderma on the deal. The available source material does not include further details on deal structure, closing timeline, or regulatory approvals, and those items should be confirmed against the company's announcement or regulatory filings.
Blackstone, which holds an investment in ZO Skin Health, is among the sellers, alongside other shareholders. For institutional investors, the transaction offers a reference point for valuations in the U.S. medical aesthetics and dermatology skincare segment, where a $1.5 billion price tag marks a meaningful exit for a private equity-backed asset.
Law360 reported that Ropes & Gray acted as legal counsel to Galderma on the deal. The available source material does not include further details on deal structure, closing timeline, or regulatory approvals, and those items should be confirmed against the company's announcement or regulatory filings.
Blackstone, which holds an investment in ZO Skin Health, is among the sellers, alongside other shareholders. For institutional investors, the transaction offers a reference point for valuations in the U.S. medical aesthetics and dermatology skincare segment, where a $1.5 billion price tag marks a meaningful exit for a private equity-backed asset.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.